Outcomes of breakthrough COVID-19 infections in patients with hematologic malignancies
Open Access
- 27 September 2023
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (19) , 5691-5697
Abstract
Patients with hematologic malignancies have both an increased risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and higher morbidity/mortality. They have lower seroconversion rates after vaccination, potentially leading to inferior coronavirus disease 2019 (COVID-19) outcomes, despite vaccination. We consequently evaluated the clinical outcomes of COVID-19 infections in 243 vaccinated and 175 unvaccinated patients with hematologic malignancies. Hospitalization rates were lower in the vaccinated group when compared with the unvaccinated group (31.3% vs 52.6%). However, the rates of COVID-19–associated death were similar at 7.0% and 8.6% in vaccinated and unvaccinated patients, respectively. By univariate logistic regression, females, older patients, and individuals with higher modified Charlson Comorbidity Index scores were at a higher risk of death from COVID-19 infections. To account for the nonrandomized nature of COVID-19 vaccination status, a propensity score weighting approach was used. In the final propensity-weighted model, vaccination status was not significantly associated with the risk of death from COVID-19 infections but was associated with the risk of hospitalization. The predicted benefit of vaccination was an absolute decrease in the probability of death and hospitalization from COVID-19 infections by 2.3% and 22.9%, respectively. In conclusion, COVID-19 vaccination status in patients with hematologic malignancies was associated with a decreased risk of hospitalization but not associated with a decreased risk of death from COVID-19 infections in the pre-Omicron era. Protective strategies, in addition to immunization, are warranted in this vulnerable patient population.Keywords
This publication has 37 references indexed in Scilit:
- Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patientsBlood, 2020
- Socio-economic status and COVID-19–related cases and fatalitiesPublic Health, 2020
- Chemotherapy and COVID-19 Outcomes in Patients With CancerJournal of Clinical Oncology, 2020
- Factors Associated With US Adults’ Likelihood of Accepting COVID-19 VaccinationJAMA Network Open, 2020
- COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort studyThe Lancet Oncology, 2020
- Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort studyThe Lancet Haematology, 2020
- The outcome of COVID‐19 in patients with hematological malignancyJournal of Medical Virology, 2020
- Survival study of hospitalised patients with concurrent COVID‐19 and haematological malignanciesBritish Journal of Haematology, 2020
- Tutorial in biostatistics: competing risks and multi‐state modelsStatistics in Medicine, 2006
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987